Collagenase Total Occlusion-2 Trial (CTO-2)
A prospective, multi-center, double blind, placebo-controlled, phase III study, evaluating acute intra-coronary injected collagenase prior to routine standard-of-care percutaneous revascularization procedures in subjects with chronic total coronary artery occlusions (CTOs).
|Study Design:||Allocation: Randomized
Masking: Double Blind (Subject, Investigator)
|Official Title:||Collagenase Total Occlusion-2 Trial|
- Seattle Angina Questionnaire [ Time Frame: Screening and 2 months post procedure ] [ Designated as safety issue: No ]Change in angina symptoms as defined by the Seattle Angina Questionnaire (SAQ).
|Study Start Date:||June 2013|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Local intra-coronary administration of MZ-004 at or into the CTO
Other Name: MZ-004
|Placebo Comparator: saline||
Local intra-coronary administration of saline at or into the CTO